0000000000855824

AUTHOR

Annika ÅLgars

showing 3 related works from this author

EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer

2018

Epidermal growth factor receptor (EGFR) gene copy number (GCN) increase is associated with a favorable anti-EGFR antibody treatment response in RAS wild-type metastatic colorectal cancer. However, there are limited and comparative data regarding the EGFR GCN in primary colorectal cancer tumors and corresponding metastases or the effect of anti-EGFR antibody treatment on EGFR GCN in recurrent disease. In addition, little is known about the potential EGFR GCN changes during anti-EGFR therapy in comparison with other treatment regimens. EGFR GCN was analyzed by EGFR immunohistochemistry-guided silver in situ hybridization in primary and corresponding recurrent local or metastatic tumors from 8…

Male0301 basic medicineTime FactorsColorectal cancerBLOCKADEGene DosageCetuximabmedicine.disease_causeAntineoplastic Agents Immunological0302 clinical medicinePREDICTS RESPONSEMedicineHETEROGENEITYBENEFITCopy-number variationEpidermal growth factor receptorIn Situ Hybridization FluorescenceAged 80 and overbiologyPanitumumabvasta-aineetMiddle AgedImmunohistochemistry3. Good healthErbB ReceptorsGene Expression Regulation NeoplasticTreatment OutcomeRAS MUTATIONSChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleKRASAntibodyColorectal NeoplasmsAdultgene copy numbermedicine.drug_classCETUXIMAB THERAPY3122 Cancerssilver in situ hybridizationDown-Regulationcolorectal cancerIn situ hybridizationAdenocarcinomaMonoclonal antibodyta3111Pathology and Forensic MedicineProto-Oncogene Proteins p21(ras)03 medical and health sciencesKRASHumansWILD-TYPEMETAANALYSISAgedRetrospective Studiessyöpähoidotbusiness.industrymedicine.diseaseta3122Blockadeperäsuolisyöpä030104 developmental biologymonoclonal antibodyMutationCancer researchbiology.protein3111 BiomedicineNeoplasm Recurrence Localbusinessepidermal growth factor receptorACQUIRED-RESISTANCEHuman Pathology
researchProduct

Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study

2022

Abstract Background Outcomes after metastasectomy for metastatic colorectal cancer (mCRC) vary with RAS and BRAF mutational status, but their effects on resectability and conversion rates have not been extensively studied. Methods This substudy of the prospective RAXO trial included 906 patients recruited between 2011 and 2018. We evaluated repeated centralised resectability assessment, conversion/resection rates and overall survival (OS), according to RAS and BRAF status. Results Patients included 289 with RAS and BRAF wild-type (RAS and BRAFwt), 529 with RAS mutated (RASmt) and 88 with BRAF mutated (BRAFmt) mCRC. Metastatic prevalence varied between the RAS and BRAFwt/RASmt/BRAFmt groups,…

Proto-Oncogene Proteins B-rafCancer ResearchBEVACIZUMAB3122 Cancerscolorectal cancerbiomarkkerit3121 Internal medicineleikkaushoitoLIVER METASTASESetäpesäkkeetsurgical oncologyKRASHumansmetastasisProspective StudiesFOLFOXIRIpaksusuolisyöpäCancer och onkologiRectal NeoplasmsCOLON-CANCERMetastasectomyennusteetCHEMOTHERAPYOncologysyöpägeenithoitotuloksetCancer and OncologyColonic NeoplasmsMutationSURVIVALsyöpätauditonkologiaColorectal Neoplasmsprognostic markers
researchProduct

Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer.

2013

To characterize the stage-specific prognostic relevance of preoperative systemic inflammatory response, defined by C-reactive protein (CRP), in colon cancer (CC) patients.Data from CC patients operated on from 1998 to 2007 at three hospitals from three different Nordic countries were collected retrospectively from national registries, local databases and/or patient records. Patients with emergency surgery, infection or auto-immune disease were excluded. Associations between clinical or histopathological variables and CRP were assessed. Patients were followed from the date of surgery to death or end of follow-up. Disease-specific survival (DSS) was the main endpoint.In total, 525 patients wi…

AdultMalemedicine.medical_specialtyColorectal cancerIncreased C-reactive proteinDiseaseGastroenterologyInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingStage (cooking)Stage specificSurvival rateAgedNeoplasm StagingRetrospective StudiesAged 80 and overbusiness.industryElevated crpRetrospective cohort studyHematologyGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurgerySurvival RateC-Reactive ProteinOncologyLymphatic MetastasisColonic NeoplasmsFemaleNeoplasm GradingbusinessFollow-Up StudiesActa oncologica (Stockholm, Sweden)
researchProduct